<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="EN"><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title>PLoS ONE</journal-title><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">08-PONE-RA-07755R1</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0005638</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Genetics and Genomics/Cancer Genetics</subject><subject>Neurological Disorders/Neuro-Oncology</subject><subject>Oncology/Neuro-Oncology</subject></subj-group></article-categories><title-group><article-title>Absence of <italic>AKT1</italic> Mutations in Glioblastoma</article-title><alt-title alt-title-type="running-head"><italic>AKT1</italic> Mutations in Glioblastoma</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Bleeker</surname><given-names>Fonnet E.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="cor1"><sup>&#x0002a;</sup></xref></contrib><contrib contrib-type="author"><name><surname>Lamba</surname><given-names>Simona</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Zanon</surname><given-names>Carlo</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>van Tilborg</surname><given-names>Angela A.</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Leenstra</surname><given-names>Sieger</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Troost</surname><given-names>Dirk</given-names></name><xref ref-type="aff" rid="aff6"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Hulsebos</surname><given-names>Theo</given-names></name><xref ref-type="aff" rid="aff7"><sup>7</sup></xref></contrib><contrib contrib-type="author"><name><surname>Vandertop</surname><given-names>W. Peter</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff8"><sup>8</sup></xref></contrib><contrib contrib-type="author"><name><surname>Bardelli</surname><given-names>Alberto</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff9"><sup>9</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>Neurosurgical Center Amsterdam, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands</addr-line></aff><aff id="aff2"><label>2</label><addr-line>Laboratory of Molecular Genetics, The Oncogenomics Center, Institute for Cancer Research and Treatment, University of Torino Medical School, University of Torino, Medical School, Candiolo (TO), Italy</addr-line></aff><aff id="aff3"><label>3</label><addr-line>Department of Pathology, Erasmus Medical Center, Rotterdam, The Netherlands</addr-line></aff><aff id="aff4"><label>4</label><addr-line>Department of Neurosurgery, Erasmus Medical Center, Rotterdam, The Netherlands</addr-line></aff><aff id="aff5"><label>5</label><addr-line>Department of Neurosurgery, St. Elisabeth Ziekenhuis Tilburg, Tilburg, The Netherlands</addr-line></aff><aff id="aff6"><label>6</label><addr-line>Department of Neuropathology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands</addr-line></aff><aff id="aff7"><label>7</label><addr-line>Department of Neurogenetics, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands</addr-line></aff><aff id="aff8"><label>8</label><addr-line>Neurosurgical Center Amsterdam, Location VU University Medical Center, Amsterdam, The Netherlands</addr-line></aff><aff id="aff9"><label>9</label><addr-line>FIRC Institute of Molecular Oncology, Milan, Italy</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Hoheisel</surname><given-names>J&#x000f6;rg</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">Deutsches Krebsforschungszentrum, Germany</aff><author-notes><corresp id="cor1">&#x0002a; E-mail: <email>f.e.bleeker@amc.uva.nl</email></corresp><fn fn-type="con"><p>Conceived and designed the experiments: FB AAGvT AB. Performed the experiments: FB SL CZ. Analyzed the data: FB SL. Contributed reagents/materials/analysis tools: FB AAGvT SL DT TH WPV AB. Wrote the paper: FB WPV AB.</p></fn></author-notes><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>20</day><month>5</month><year>2009</year></pub-date><volume>4</volume><issue>5</issue><elocation-id>e5638</elocation-id><history><date date-type="received"><day>9</day><month>12</month><year>2008</year></date><date date-type="accepted"><day>9</day><month>4</month><year>2009</year></date></history><copyright-statement>Bleeker et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</copyright-statement><copyright-year>2009</copyright-year><abstract><sec><title>Background</title><p>Oncogenic activation of the PI3K signalling pathway plays a pivotal role in the development of glioblastoma multiforme (GBM). A central node in PI3K downstream signalling is controlled by the serine-threonine kinase AKT1. A somatic mutation affecting residue E17 of the <italic>AKT1</italic> gene has recently been identified in breast and colon cancer. The E17K change results in constitutive AKT1 activation, induces leukaemia in mice, and accordingly, may be therapeutically exploited to target the PI3K pathway. Assessing whether AKT1 is activated by somatic mutations in GBM is relevant to establish its role in this aggressive disease.</p></sec><sec><title>Methodology/Principal Findings</title><p>We performed a systematic mutational analysis of the complete coding sequence of the AKT1 gene in a panel of 109 tumor GBM samples and nine high grade astrocytoma cell lines. However, no somatic mutations were detected in the coding region of <italic>AKT1</italic>.</p></sec><sec><title>Conclusions/Significance</title><p>Our data indicate that in GBM oncogenic deregulation of the PI3K pathway does not involve somatic mutations in the coding region of <italic>AKT1</italic>.</p></sec></abstract><counts><page-count count="3"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>A number of genetic and functional evidences have unequivocally established the importance of the PI3K pathway in human cancer <xref ref-type="bibr" rid="pone.0005638-Brugge1">&#x0005b;1&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005638-Wood1">&#x0005b;2&#x0005d;</xref>. For example oncogenic deregulation of the PI3K pathway plays a central role in the development of Glioblastoma Multiforme (GBM) as shown by the fact that many of its members are genetically altered <xref ref-type="bibr" rid="pone.0005638-Knobbe1">&#x0005b;3&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005638-Kita1">&#x0005b;4&#x0005d;</xref>. Two main regulators, the lipid kinase PIK3CA and the lipid phosphatase PTEN, control this signalling pathway. We and other have shown that the <italic>PIK3CA</italic> gene is mutated in many tumour types, including GBM <xref ref-type="bibr" rid="pone.0005638-Kita1">&#x0005b;4&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0005638-Benvenuti1">&#x0005b;7&#x0005d;</xref>. The corresponding mutations result in activation of the PI3K catalytic activity and constitutive downstream signalling. The tumour suppressor gene PTEN encodes for a lipid phopshatase which counteracts the effect of PI3K thus negatively controlling signalling. <italic>PTEN</italic> is mutationally and transcriptionally inactivated in many different tumour types, including GBM <xref ref-type="bibr" rid="pone.0005638-Li1">&#x0005b;8&#x0005d;</xref>. In most tumour lineages, including GBMs <italic>PIK3CA</italic> and <italic>PTEN</italic> mutations occur in a mutually exclusive manner <xref ref-type="bibr" rid="pone.0005638-Hartmann1">&#x0005b;6&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005638-Saal1">&#x0005b;9&#x0005d;</xref>. This suggests that they exert overlapping cellular functions, and in fact, both control the cellular levels of phosphatidylinositol-3-phosphate (PIP3) <xref ref-type="bibr" rid="pone.0005638-Stephens1">&#x0005b;10&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005638-Maehama1">&#x0005b;11&#x0005d;</xref>. Other mechanisms of activation of the PI3K pathway include alterations in tyrosine kinase receptors acting upstream in the signalling cascade. This is the case for the receptor tyrosine kinase <italic>EGFR</italic> which can be activated by gene amplification and/or mutations <xref ref-type="bibr" rid="pone.0005638-Lee1">&#x0005b;12&#x0005d;</xref>. Both missense point mutations and large extracellular domain deletions (<italic>EGFRvIII</italic>, which due to alternative splicing misses exon 2&#x02013;7) affecting the <italic>EGFR</italic> gene have been reported at considerable frequency in GBM and result in constitutive activation of the receptor and of the underlying PI3K pathway <xref ref-type="bibr" rid="pone.0005638-Lee1">&#x0005b;12&#x0005d;</xref>.</p><p>Downstream in the signaling cascade, PI3K and PTEN control PIP3, which activates downstream effector molecules, such as the serine-threonine kinase AKT. A recent sequencing study led to the identification of oncogenic somatic mutations in the pleckstrin homology domain of <italic>AKT1</italic> in breast, colon and ovarian cancer <xref ref-type="bibr" rid="pone.0005638-Carpten1">&#x0005b;13&#x0005d;</xref>. Interestingly, in all cases examined the same mutation E17K was identified. This mutation alters the electrostatic interactions of the pocket and constitutively activates AKT1 in a PI3K-independent manner. By this mechanism, it transforms rodent cells in vitro and can induce leukaemia in mice <xref ref-type="bibr" rid="pone.0005638-Carpten1">&#x0005b;13&#x0005d;</xref>. Recently, we and others assessed the mutational status of the E17K mutation in different tumor types <xref ref-type="bibr" rid="pone.0005638-Malanga1">&#x0005b;14&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0005638-Schuller1">&#x0005b;17&#x0005d;</xref>, confirming the mutations in breast and colon, and most interestingly revealing mutations in lung cancer <xref ref-type="bibr" rid="pone.0005638-Malanga1">&#x0005b;14&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005638-Bleeker1">&#x0005b;15&#x0005d;</xref>. On the contrary, we did not detect any mutations affecting the hotspot residue E17 in a panel of 128 GBMs <xref ref-type="bibr" rid="pone.0005638-Bleeker1">&#x0005b;15&#x0005d;</xref>. We noted that, GBMs do exhibit a different mutation spectrum for some genes compared to other tumor types. For example, most <italic>EGFR</italic> and <italic>ERBB2</italic> mutations in lung cancer are found in the kinase domain <xref ref-type="bibr" rid="pone.0005638-Lynch1">&#x0005b;18&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005638-Stephens2">&#x0005b;19&#x0005d;</xref>, whereas these genes are predominantly mutated in the extracellular domain in GBM <xref ref-type="bibr" rid="pone.0005638-Lee1">&#x0005b;12&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005638-Parsons1">&#x0005b;20&#x0005d;</xref>. This led us to speculate that GBMs might bear mutations in other regions of the <italic>AKT1</italic> gene. To definitively assess this hypothesis, we successfully sequenced the complete coding sequence of <italic>AKT1</italic> in 109 GBM tumor samples and nine high grade astrocytoma cell lines.</p></sec><sec id="s2"><title>Results and Discussion</title><p>We sequenced the complete coding sequence of the <italic>AKT1</italic> gene in a set of 109 GBM tumors and 9 high grade astrocytoma cell lines. Primers were designed to amplify and sequence the genomic region corresponding to all coding exons of <italic>AKT1</italic>, including exon 4, where the E17K residue is located. Amplicons included at least 15 intronic bases at both the 5&#x02032; and 3&#x02032; ends encompassing the splicing donor and acceptor sites. A total of 1535 PCR products, spanning 628 kb of tumour genomic DNA, were generated and subjected to direct sequencing. Sequencing was performed single stranded with either forward or reverser primer. Identified changes were independently confirmed by another round of PCR and sequencing.</p><p>Previous work focusing on the mutational analysis of exon 4 did not identify any E17K mutation in 128 GBM samples <xref ref-type="bibr" rid="pone.0005638-Bleeker1">&#x0005b;15&#x0005d;</xref>. Importantly, we extended the mutational analysis for these tumors to all other coding exons of <italic>AKT1</italic>, but no somatic mutations were found.</p><p>Our tumor set was validated by previous mutational profiling of common cancer genes, including the <italic>IDH1</italic> gene <xref ref-type="bibr" rid="pone.0005638-Bleeker2">&#x0005b;21&#x0005d;</xref>. Furthermore, we found a number of previous reported SNPs in our samples (rs17846822, rs34664585, rs3730358, rs3730368, rs2494737, rs2494735, rs34670300, rs3730361, rs3730329, rs3730329, rs2494732). In addition, we identified three novel germline changes (IVS8-12C&#x0003e;T, R200H and W333&#x0002a;) at low frequency, they were found only once in different samples. Our work is focused on somatic mutations and therefore, we did not study these changes in further detail.</p><p>While previous studies have focused mainly on the hotspot mutation site <italic>AKT1<sup>E17</sup></italic>or the serine and threonine phosphorylation sites <xref ref-type="bibr" rid="pone.0005638-Knobbe1">&#x0005b;3&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005638-Bleeker1">&#x0005b;15&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005638-Schuller1">&#x0005b;17&#x0005d;</xref>, this work is the first to show in a large panel of GBMs that the coding sequence of the AKT1 is not somatically mutated in this tumour lineage. Although the promoter region and/or the 5&#x02032; and 3&#x02032; UTR of <italic>AKT1</italic> may contain mutations, our data indicate that in GBM oncogenic deregulation of the PI3K pathway does not involve mutations in the coding region of <italic>AKT1</italic>.</p></sec><sec sec-type="materials|methods" id="s3"><title>Materials and Methods</title><sec id="s3a"><title>Tumor sample, Ethics Statement and Isolation of Genomic DNA</title><p>All samples were collected from patients undergoing brain tumor surgery in the Academic Medical Center (Amsterdam, The Netherlands). Oral consent for removal of the tissue and its storage in the tumor bank for research purposes was obtained and documented in the patient's medical chart. Individual consent for this specific project was waivered by our ethics committee because the research was performed on &#x02018;waste&#x02019; material, stored in a coded fashion. Patient characteristics are displayed in <xref ref-type="table" rid="pone-0005638-t001">Table 1</xref>. Tumor samples were included only if at least 80&#x00025; of the sample consisted of cancer cells, as verified by H&#x00026;E staining.</p><table-wrap id="pone-0005638-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005638.t001</object-id><label>Table 1</label><caption><title>Characteristics of 109 GBM tumor samples.</title></caption><graphic id="pone-0005638-t001-1" xlink:href="pone.0005638.t001"/><table frame="hsides" rules="groups" alternate-form-of="pone-0005638-t001-1"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><tbody><tr><td align="left" rowspan="1" colspan="1">GBM subclasses</td><td align="left" rowspan="1" colspan="1">primary</td><td align="left" rowspan="1" colspan="1">94</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">secondary</td><td align="left" rowspan="1" colspan="1">15</td></tr><tr><td align="left" rowspan="1" colspan="1">Patient sex</td><td align="left" rowspan="1" colspan="1">female</td><td align="left" rowspan="1" colspan="1">47</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">male</td><td align="left" rowspan="1" colspan="1">62</td></tr><tr><td align="left" rowspan="1" colspan="1">Patient age</td><td align="left" rowspan="1" colspan="1">mean age (years)</td><td align="left" rowspan="1" colspan="1">53.6</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">median age (years)</td><td align="left" rowspan="1" colspan="1">55</td></tr></tbody></table></table-wrap><p>Nine astrocytoma cell lines were included: the cell lines U87MG, U118MG, U251MG, U373MG, T98G (ATCC, Middlesex, United Kingdom), SKMG-3 (a gift of Dr Christopher Y. Thomas, University of Virginia Division of Hematology/Oncology, Charlottesville, VA), SF763 (gift of Dr M.L. Lamfers, Department of Neurosurgery, Free University, Amsterdam, The Netherlands), SF126 (a gift of Dr C. Van Bree, University of Amsterdam, Laboratory for Experimental Oncology and Radiation Biology, Amsterdam, The Netherlands), Gli-6 was derived from our own laboratory. Genomic DNA was isolated as previously described <xref ref-type="bibr" rid="pone.0005638-Balakrishnan1">&#x0005b;22&#x0005d;</xref>.</p></sec><sec id="s3b"><title>PCR, Sequencing and Analysis</title><p>PCR primers were designed using Primer 3 (<ext-link ext-link-type="uri" xlink:href="http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi">http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi</ext-link>), and synthesized by Invitrogen/Life Technologies, Inc. (Paisley, England) (<xref ref-type="table" rid="pone-0005638-t002">Table 2</xref>). PCR primers that amplify the selected exons and the flanking intronic sequences, including splicing donor and acceptor regions, were used and PCR products were on average 381 bps in length. PCRs were performed in both 384- and 96-well formats in 5- or 10-uL reaction volumes, respectively, containing 0.25 mmol/L deoxynucleotide triphosphates, 1 umol/L each of the forward and reverse primers, 6&#x00025; DMSO, 1&#x000d7; PCR buffer, 1 ng/uL DNA, and 0.05 unit/uL Platinum Taq (Invitrogen/Life Technologies). A touchdown PCR program was used for PCR amplification (Peltier Thermocycler, PTC-200, MJ Research, Bio-Rad Laboratories, Inc., Italy).</p><table-wrap id="pone-0005638-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005638.t002</object-id><label>Table 2</label><caption><title>Primer details to sequence the coding sequence of AKT1.</title></caption><graphic id="pone-0005638-t002-2" xlink:href="pone.0005638.t002"/><table frame="hsides" rules="groups" alternate-form-of="pone-0005638-t002-2"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Exon</td><td align="left" rowspan="1" colspan="1">Forward Primer Sequence</td><td align="left" rowspan="1" colspan="1">Reverse Primer Sequence</td><td align="left" rowspan="1" colspan="1">Sequencing Primer Sequence</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">GTCAGAGAGCTTAGAGGGATGG</named-content></td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">GGCACAGGCACTCACAGA</named-content></td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">AGTGGGTCTCTGGCTCACC</named-content></td></tr><tr><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">AGTCTGCCTTCCCGTTGAC</named-content></td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">CAGCCAGTGCTTGTTGCTT</named-content></td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">GTTTCTGTCGCTGGCCCTA</named-content></td></tr><tr><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">AGGCTTGGAGAGAGGAAGAGAT</named-content></td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">GGAGTGAGGATGGCTACAGG</named-content></td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">CTGGTGGGTGGTATGCAAG</named-content></td></tr><tr><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">AGGGCTGTCTCTGGGAACC</named-content></td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">TGGAGTGCTGAGTGTCTCCTG</named-content></td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">GGGTGGGTGAAAGACGTG</named-content></td></tr><tr><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">GTTCCCTGTAAGCCTGGACTC</named-content></td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">TAAAGCAGGGCTGGGTGA</named-content></td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">GCTCTGCCTCCGACTCTG</named-content></td></tr><tr><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">CCGCTACTACGCCATGAAGA</named-content></td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">ACATCGTCCCCTAGAGACAGC</named-content></td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">CATGAAGATCCTCAAGAAGGAAG</named-content></td></tr><tr><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">AACACTCCTTGGCACCTCAG</named-content></td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">TAACTCAGCAGGAACAAGTCACC</named-content></td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">ATCAGGCGACGTGGTATCAA</named-content></td></tr><tr><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">AGTTAGGGCTTCTGAGACTTTCC</named-content></td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">CTTGTCCAGCATGAGGTTCTC</named-content></td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">GTCCCTTCCCTGTGCAATG</named-content></td></tr><tr><td align="left" rowspan="1" colspan="1">11</td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">CTACCTGCACTCGGAGAAGAAC</named-content></td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">CAGGACTCGGCATCAAGG</named-content></td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">GCACAGAGAGGACACAGCATT</named-content></td></tr><tr><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">CTGAGCACACGCAATGCT</named-content></td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">GACATCAAGCTTTGGCTATCAGT</named-content></td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">AATGCTGTGTCCTCTCTGTGC</named-content></td></tr><tr><td align="left" rowspan="1" colspan="1">13</td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">GTGAGCTCTGTGGTGCTTTG</named-content></td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">GCGTGAGTGTGGATATGTGG</named-content></td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">GCCCTACATCACAGGAGGAA</named-content></td></tr><tr><td align="left" rowspan="1" colspan="1">14</td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">GCTTGCTGCTCTCTGACATC</named-content></td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">AGGCCTCTCTGAGTGTGGA</named-content></td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">ATCCAGGTGCTTTGAAGGTCT</named-content></td></tr><tr><td align="left" rowspan="1" colspan="1">15</td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">AGGTCCCTGTGTCAATCTGTG</named-content></td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">CTCAAATGCACCCGAGAAATA</named-content></td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">GAGGTTGGCTTCCTACTGGAG</named-content></td></tr></tbody></table><table-wrap-foot><fn id="nt101"><label/><p>Primers in 5&#x02032; to 3&#x02032; direction.</p></fn></table-wrap-foot></table-wrap><p>PCR conditions were as follows: 94&#x000b0;C for 2 min; three cycles of 94&#x000b0;C for 15 s, 64&#x000b0;C for 30 s, 70&#x000b0;C for 30 s; three cycles of 94&#x000b0;C for 15 s, 61&#x000b0;C for 30 s, 70&#x000b0;C for 30 s; three cycles of 94&#x000b0;C for 15 s, 58&#x000b0;C for 30 s, 70&#x000b0;C for 30 s; and 35 cycles of 94&#x000b0;C for 15 s, 57&#x000b0;C for 30 s, and 70&#x000b0;C for 30 s, followed by 70&#x000b0;C for 5 min and 12&#x000b0;C thereafter. PCR products were purified using AMPure (Agencourt Bioscience Corp., Beckman Coulter S.p.A, Milan, Italy). Cycle sequencing was carried out using BigDye Terminator v3.1 Cycle Sequencing kit (Applied Biosystems, Foster City, CA) with an initial denaturation at 97&#x000b0;C for 3 min, followed by 28 cycles of 97&#x000b0;C for 10 s, 50&#x000b0;C for 20 s, and 60&#x000b0;C for 2 min. Sequencing products were purified using CleanSeq (Agencourt Bioscience, Beckman Coulter) and analyzed on a 3730 DNA Analyzer, ABI capillary electrophoresis system (Applied Biosystems). Sequence traces were analyzed using the Mutation Surveyor software package (SoftGenetics, State College, PA).</p></sec></sec></body><back><ref-list><title>References</title><ref id="pone.0005638-Brugge1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brugge</surname><given-names>J</given-names></name><name><surname>Hung</surname><given-names>MC</given-names></name><name><surname>Mills</surname><given-names>GB</given-names></name></person-group><year>2007</year><article-title>A new mutational AKTivation in the PI3K pathway.</article-title><source>Cancer cell</source><volume>12</volume><fpage>104</fpage><lpage>107</lpage><pub-id pub-id-type="pmid">17692802</pub-id></citation></ref><ref id="pone.0005638-Wood1"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wood</surname><given-names>LD</given-names></name><name><surname>Parsons</surname><given-names>DW</given-names></name><name><surname>Jones</surname><given-names>S</given-names></name><name><surname>Lin</surname><given-names>J</given-names></name><name><surname>Sjoblom</surname><given-names>T</given-names></name><etal/></person-group><year>2007</year><article-title>The genomic landscapes of human breast and colorectal cancers.</article-title><source>Science</source><volume>318</volume><fpage>1108</fpage><lpage>1113</lpage><pub-id pub-id-type="pmid">17932254</pub-id></citation></ref><ref id="pone.0005638-Knobbe1"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Knobbe</surname><given-names>CB</given-names></name><name><surname>Trampe-Kieslich</surname><given-names>A</given-names></name><name><surname>Reifenberger</surname><given-names>G</given-names></name></person-group><year>2005</year><article-title>Genetic alteration and expression of the phosphoinositol-3-kinase/Akt pathway genes PIK3CA and PIKE in human glioblastomas.</article-title><source>Neuropathol Appl Neurobiol</source><volume>31</volume><fpage>486</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">16150119</pub-id></citation></ref><ref id="pone.0005638-Kita1"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kita</surname><given-names>D</given-names></name><name><surname>Yonekawa</surname><given-names>Y</given-names></name><name><surname>Weller</surname><given-names>M</given-names></name><name><surname>Ohgaki</surname><given-names>H</given-names></name></person-group><year>2007</year><article-title>PIK3CA alterations in primary (de novo) and secondary glioblastomas.</article-title><source>Acta Neuropathol</source><volume>113</volume><fpage>295</fpage><lpage>302</lpage><pub-id pub-id-type="pmid">17235514</pub-id></citation></ref><ref id="pone.0005638-Samuels1"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Samuels</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Bardelli</surname><given-names>A</given-names></name><name><surname>Silliman</surname><given-names>N</given-names></name><name><surname>Ptak</surname><given-names>J</given-names></name><etal/></person-group><year>2004</year><article-title>High frequency of mutations of the PIK3CA gene in human cancers.</article-title><source>Science</source><volume>304</volume><fpage>554</fpage><pub-id pub-id-type="pmid">15016963</pub-id></citation></ref><ref id="pone.0005638-Hartmann1"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hartmann</surname><given-names>C</given-names></name><name><surname>Bartels</surname><given-names>G</given-names></name><name><surname>Gehlhaar</surname><given-names>C</given-names></name><name><surname>Holtkamp</surname><given-names>N</given-names></name><name><surname>von Deimling</surname><given-names>A</given-names></name></person-group><year>2005</year><article-title>PIK3CA mutations in glioblastoma multiforme.</article-title><source>Acta Neuropathol</source><volume>109</volume><fpage>639</fpage><lpage>642</lpage><pub-id pub-id-type="pmid">15924253</pub-id></citation></ref><ref id="pone.0005638-Benvenuti1"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Benvenuti</surname><given-names>S</given-names></name><name><surname>Frattini</surname><given-names>M</given-names></name><name><surname>Arena</surname><given-names>S</given-names></name><name><surname>Zanon</surname><given-names>C</given-names></name><name><surname>Cappelletti</surname><given-names>V</given-names></name><etal/></person-group><year>2008</year><article-title>PIK3CA cancer mutations display gender and tissue specificity patterns.</article-title><source>Hum Mutat</source><volume>29</volume><fpage>284</fpage><lpage>288</lpage><pub-id pub-id-type="pmid">18022911</pub-id></citation></ref><ref id="pone.0005638-Li1"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Yen</surname><given-names>C</given-names></name><name><surname>Liaw</surname><given-names>D</given-names></name><name><surname>Podsypanina</surname><given-names>K</given-names></name><name><surname>Bose</surname><given-names>S</given-names></name><etal/></person-group><year>1997</year><article-title>PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer.</article-title><source>Science</source><volume>275</volume><fpage>1943</fpage><lpage>1947</lpage><pub-id pub-id-type="pmid">9072974</pub-id></citation></ref><ref id="pone.0005638-Saal1"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Saal</surname><given-names>LH</given-names></name><name><surname>Holm</surname><given-names>K</given-names></name><name><surname>Maurer</surname><given-names>M</given-names></name><name><surname>Memeo</surname><given-names>L</given-names></name><name><surname>Su</surname><given-names>T</given-names></name><etal/></person-group><year>2005</year><article-title>PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma.</article-title><source>Cancer Res</source><volume>65</volume><fpage>2554</fpage><lpage>2559</lpage><pub-id pub-id-type="pmid">15805248</pub-id></citation></ref><ref id="pone.0005638-Stephens1"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stephens</surname><given-names>LR</given-names></name><name><surname>Hughes</surname><given-names>KT</given-names></name><name><surname>Irvine</surname><given-names>RF</given-names></name></person-group><year>1991</year><article-title>Pathway of phosphatidylinositol(3,4,5)-trisphosphate synthesis in activated neutrophils.</article-title><source>Nature</source><volume>351</volume><fpage>33</fpage><lpage>39</lpage><pub-id pub-id-type="pmid">1851250</pub-id></citation></ref><ref id="pone.0005638-Maehama1"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Maehama</surname><given-names>T</given-names></name><name><surname>Dixon</surname><given-names>JE</given-names></name></person-group><year>1998</year><article-title>The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate.</article-title><source>J Biol Chem</source><volume>273</volume><fpage>13375</fpage><lpage>13378</lpage><pub-id pub-id-type="pmid">9593664</pub-id></citation></ref><ref id="pone.0005638-Lee1"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>JC</given-names></name><name><surname>Vivanco</surname><given-names>I</given-names></name><name><surname>Beroukhim</surname><given-names>R</given-names></name><name><surname>Huang</surname><given-names>JH</given-names></name><name><surname>Feng</surname><given-names>WL</given-names></name><etal/></person-group><year>2006</year><article-title>Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain.</article-title><source>PLoS Med</source><volume>3</volume><fpage>e485</fpage><pub-id pub-id-type="pmid">17177598</pub-id></citation></ref><ref id="pone.0005638-Carpten1"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Carpten</surname><given-names>JD</given-names></name><name><surname>Faber</surname><given-names>AL</given-names></name><name><surname>Horn</surname><given-names>C</given-names></name><name><surname>Donoho</surname><given-names>GP</given-names></name><name><surname>Briggs</surname><given-names>SL</given-names></name><etal/></person-group><year>2007</year><article-title>A transforming mutation in the pleckstrin homology domain of AKT1 in cancer.</article-title><source>Nature</source><volume>448</volume><fpage>439</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">17611497</pub-id></citation></ref><ref id="pone.0005638-Malanga1"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Malanga</surname><given-names>D</given-names></name><name><surname>Scrima</surname><given-names>M</given-names></name><name><surname>De Marco</surname><given-names>C</given-names></name><name><surname>Fabiani</surname><given-names>F</given-names></name><name><surname>De Rosa</surname><given-names>N</given-names></name><etal/></person-group><year>2007</year><article-title>Activating E17K mutation in the gene encoding the protein kinase AKT in a subset of squamous cell carcinoma of the lung.</article-title><source>Cell Cycle</source><volume>7</volume><fpage>665</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">18256540</pub-id></citation></ref><ref id="pone.0005638-Bleeker1"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bleeker</surname><given-names>FE</given-names></name><name><surname>Felicioni</surname><given-names>L</given-names></name><name><surname>Buttitta</surname><given-names>F</given-names></name><name><surname>Lamba</surname><given-names>S</given-names></name><name><surname>Cardone</surname><given-names>L</given-names></name><etal/></person-group><year>2008</year><article-title>AKT1(E17K) in human solid tumours.</article-title><source>Oncogene</source><volume>27</volume><fpage>5648</fpage><lpage>5650</lpage></citation></ref><ref id="pone.0005638-Kim1"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>MS</given-names></name><name><surname>Jeong</surname><given-names>EG</given-names></name><name><surname>Yoo</surname><given-names>NJ</given-names></name><name><surname>Lee</surname><given-names>SH</given-names></name></person-group><year>2008</year><article-title>Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias.</article-title><source>Br J Cancer</source><volume>98</volume><fpage>1533</fpage><lpage>1535</lpage><pub-id pub-id-type="pmid">18392055</pub-id></citation></ref><ref id="pone.0005638-Schuller1"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schuller</surname><given-names>U</given-names></name><name><surname>Ruiter</surname><given-names>M</given-names></name><name><surname>Herms</surname><given-names>J</given-names></name><name><surname>Kretzschmar</surname><given-names>HA</given-names></name><name><surname>Grasbon-Frodl</surname><given-names>E</given-names></name></person-group><year>2008</year><article-title>Absence of mutations in the AKT1 oncogene in glioblastomas and medulloblastomas.</article-title><source>Acta Neuropathol</source><volume>115</volume><fpage>367</fpage><lpage>368</lpage><pub-id pub-id-type="pmid">18172656</pub-id></citation></ref><ref id="pone.0005638-Lynch1"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lynch</surname><given-names>TJ</given-names></name><name><surname>Bell</surname><given-names>DW</given-names></name><name><surname>Sordella</surname><given-names>R</given-names></name><name><surname>Gurubhagavatula</surname><given-names>S</given-names></name><name><surname>Okimoto</surname><given-names>RA</given-names></name><etal/></person-group><year>2004</year><article-title>Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.</article-title><source>N Engl J Med</source><volume>350</volume><fpage>2129</fpage><lpage>2139</lpage><pub-id pub-id-type="pmid">15118073</pub-id></citation></ref><ref id="pone.0005638-Stephens2"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stephens</surname><given-names>P</given-names></name><name><surname>Hunter</surname><given-names>C</given-names></name><name><surname>Bignell</surname><given-names>G</given-names></name><name><surname>Edkins</surname><given-names>S</given-names></name><name><surname>Davies</surname><given-names>H</given-names></name><etal/></person-group><year>2004</year><article-title>Lung cancer: intragenic ERBB2 kinase mutations in tumours.</article-title><source>Nature</source><volume>431</volume><fpage>525</fpage><lpage>526</lpage><pub-id pub-id-type="pmid">15457249</pub-id></citation></ref><ref id="pone.0005638-Parsons1"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Parsons</surname><given-names>DW</given-names></name><name><surname>Jones</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Lin</surname><given-names>JC</given-names></name><name><surname>Leary</surname><given-names>RJ</given-names></name><etal/></person-group><year>2008</year><article-title>An Integrated Genomic Analysis of Human Glioblastoma Multiforme.</article-title><source>Science</source><volume>321</volume><fpage>1807</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">18772396</pub-id></citation></ref><ref id="pone.0005638-Bleeker2"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bleeker</surname><given-names>FE</given-names></name><name><surname>Lamba</surname><given-names>S</given-names></name><name><surname>Leenstra</surname><given-names>S</given-names></name><name><surname>Troost</surname><given-names>D</given-names></name><name><surname>Hulsebos</surname><given-names>T</given-names></name><etal/></person-group><year>2009</year><article-title>IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors.</article-title><source>Hum Mutat</source><volume>30</volume><fpage>7</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">19117336</pub-id></citation></ref><ref id="pone.0005638-Balakrishnan1"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Balakrishnan</surname><given-names>A</given-names></name><name><surname>Bleeker</surname><given-names>FE</given-names></name><name><surname>Lamba</surname><given-names>S</given-names></name><name><surname>Rodolfo</surname><given-names>M</given-names></name><name><surname>Daniotti</surname><given-names>M</given-names></name><etal/></person-group><year>2007</year><article-title>Novel somatic and germline mutations in cancer candidate genes in glioblastoma, melanoma, and pancreatic carcinoma.</article-title><source>Cancer Res</source><volume>67</volume><fpage>3545</fpage><lpage>3550</lpage><pub-id pub-id-type="pmid">17440062</pub-id></citation></ref></ref-list><fn-group><fn fn-type="conflict"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding: </bold>This work was supported by grants from Italian Association for Cancer Research (AIRC: (AB), Italian Ministry of Health, Regione Piemonte (AB), Italian Ministry of University and Research, CRT Progetto Alfieri (AB), Association for International Cancer Research (AICR-UK: AB), EU FP6 contract 037297 (AB) and Netherlands Genomic Initiative (NGI: FB). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p></fn></fn-group></back></article> 